In hepatocellular carcinoma (HCC), a randomized phase III clinical trial, IMBRAVE 150 (NCT03434379), demonstrated significant improvements in co-primary end points, PFS and OS, using the combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF-A) compared with sorafenib (39). The gene discussed is CD274; the disease is hepatocellular carcinoma.